$ABUS News
Last published 1d ago
- 1d agoABUSArbutus Biopharma Corp - PRESS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoABUSArbutus Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireMaintained strong financial position with cash, cash equivalents and marketable securities of $337.5M as of September 30, 2026, including receipt of cash...
- 2w agoABUSArbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 InhibitorGlobeNewswireWARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease,
- 2mo agoABUSArbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per ShareGlobeNewswireWARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease,
- 2mo agoABUSArbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender OfferGlobeNewswireWARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease,
- 3mo agoABUSArbutus Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireMaintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to
- 3mo agoABUSArbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to ShareholdersGlobeNewswireArbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle ("LNP") technology against Pfizer and BioNTech
- 6mo agoABUSArbutus Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireQ1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of
- 7mo agoABUSArbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis BGlobeNewswireFast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or
- 7mo agoABUSArbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate UpdateGlobeNewswireStrong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology represents
- 8mo agoABUSROIVROIVWRoivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With ModernaGlobeNewswireModerna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will
- 8mo agoABUSROIVGenevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With ModernaGlobeNewswireModerna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will
- 12mo agoABUSArbutus Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireStrong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech litigation issued
- 1y agoABUSArbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025GlobeNewswireMultiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction
- 1y agoABUSArbutus Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireQ2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija
- 1y agoABUSArbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical FocusGlobeNewswireQilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory
- 1y agoABUSArbutus Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireImdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe
- 1y agoABUSArbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025GlobeNewswireData highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical
- 1y agoABUSArbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025GlobeNewswireFive abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company
- 1y agoABUSArbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate UpdateGlobeNewswireClaim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing
- 1y agoABUSROIVGenevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against ModernaGlobeNewswireBASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd.
- 1y agoABUSArbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEOGlobeNewswireWARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced
- 1y agoABUSArbutus Provides 2025 Corporate and Financial UpdateGlobeNewswireInitiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) --
- 1y agoABUSWhitefort Capital Sends Letter to Arbutus Biopharma Board of DirectorsBusiness WireBelieves Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explore All Options for HBV Portfolio Urges Arbutus to Commit to No Dilutive Equity Issuances
- 1y agoABUSArbutus to Participate in H.C Wainwright @ Home Virtual Fireside ChatGlobeNewswireWARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to
- 1y agoABUSArbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of InterferonGlobeNewswire50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional cure Data
- 1y agoABUSBRNSArbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis BGlobeNewswireSignificantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously23% of participants receiving
- 1y agoABUSArbutus to Present at Jefferies London Healthcare ConferenceGlobeNewswireWARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to
- 2y agoABUSArbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoABUSArbutus Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireImdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial
- 2y agoABUSArbutus to Report Third Quarter 2024 Financial Results and Provide Corporate UpdateGlobeNewswireWARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), ("Arbutus" or the "Company") a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to
- 2y agoABUSArbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024GlobeNewswireWARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), ("Arbutus" or the "Company") a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to
- 2y agoABUSArbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual ConferenceGlobeNewswireWARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise
- 2y agoABUSArbutus to Participate in Two Upcoming Investor ConferencesGlobeNewswireWARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to
- 2y agoABUSArbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoABUSArbutus Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireEnd-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I clinical trial
- 2y agoABUSArbutus to Report Second Quarter 2024 Financial Results and Provide Corporate UpdateGlobeNewswireWARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for
- 2y agoABUSBRNSBarinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis BGlobeNewswireIn the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for
- 2y agoABUSTreatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg LevelsGlobeNewswireData highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or
- 2y agoABUSArbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional CureGlobeNewswireAt the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100%
- 2y agoABUSArbutus to Participate in Jefferies Global Healthcare ConferenceGlobeNewswireWARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for
- 2y agoABUSArbutus to Present Imdusiran Data at EASL Congress 2024GlobeNewswireWARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to
- 2y agoABUSWhitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize ValueBusiness WireAsserts Arbutus' Share of Patent Infringement Claims Against Moderna and Pfizer/BioNTech is Potentially Worth Billions of Dollars and Preserving that Value Should be a Key Focus Calls on Arbutus to Cease Any Further
- 2y agoABUSArbutus to Participate in Two Upcoming Investor ConferencesGlobeNewswireWARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for
- 2y agoABUSArbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoABUSArbutus Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireEnd-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show
- 2y agoABUSArbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024GlobeNewswireWARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to
- 2y agoABUSArbutus to Report First Quarter 2024 Financial Results and Provide Corporate UpdateGlobeNewswireWARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for
- 2y agoABUSArbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaGlobeNewswireWARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for
- 2y agoABUSArbutus to Participate in Two Upcoming Investor ConferencesGlobeNewswireWARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for